Drug Profile

Intravenous immunoglobulin - Grand Shuyang Life Sciences (Chengdu)

Alternative Names: 5% IVIG; Human immunoglobulin (pH4) for intravenous injection; SUYA-IV

Latest Information Update: 24 Dec 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Registered Idiopathic thrombocytopenic purpura; Immunodeficiency disorders; Infections; Mucocutaneous lymph node syndrome; Sepsis

26 Nov 2025 Grand Shuyang Life Sciences Chengdu has patents pending for 'Method for the production of immunoglobulins for intravenous administration' in Europe
26 Nov 2025 Registered for Idiopathic thrombocytopenic purpura in China (IV) prior to November 2025 (Grand Shuyang Life Sciences (Chengdu) pipeline, November 2025)
26 Nov 2025 Registered for Immunodeficiency disorders in China (IV) prior to November 2025 (Grand Shuyang Life Sciences (Chengdu) pipeline, November 2025)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com